HUTCHMED Completes Patient Enrolment of P-III (ESLIM-01) for Primary Immune Thrombocytopenia Patients in China
Shots:
- Last patient for P-III (ESLIM-01) study enrolled on 31st Dec’22 assessing efficacy & safety of sovleplenib in 188 adult patients with ITP with expected results in H2’23
- The 1EPs of the study is the durable response rate while the 2EPs & exploratory EPs incl. ORR, the incidence of TEAEs, and patient QoL improvement which initiated enrolment in Oct’21
- Hutchmed has global rights to the molecules and plans to submit for marketing authorization with NMPA post positive outcome. The therapy is being evaluated in AIHA, indolent NHL & multiple subtypes of B-cell malignancies in China, the US & EU in multiple trials
Ref: Globe Newswire | Image: HUTCHMED
Related News:- HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
